Home
About Us
Management
Board of Directors
News and Publications
Technology
KiNativ Website
ActivX Probes Website
Contact Us
News
Management
Board of Directors
News
ActivX News Releases
03/11/19
ActivX Biosciences reports key findings that could impact the use of clinically approved CDK4/6 inhibitors in the treatment of cancer patients
02/22/17
ActivX Biosciences, Inc. Appoints Hugh Rosen Chairman & President; John Kozarich Transitions to New Role
10/20/16
ActivX Biosciences Publishes Two Key Articles Demonstrating Breadth of Applications for KiNativ® Technology in Drug Discovery
09/23/14
John W. Kozarich Receives Director of the Year Awards 2014
June/2013
ASSAY and Drug Development Technologies Interview with John W. Kozarich - by Vicki Glaser
02/08/10
Thermo Fisher Scientific Licenses Novel Activity-Based Protein Profiling Technology from ActivX Biosciences
01/04/10
ActivX Biosciences Head Receives Distinguished Scientist Award
08/21/08
ActivX Biosciences, Inc. Announces Positive Phase Ib and IIa Clinical Trial Results for KRP-104, a Flexible Dosing DPP-4 Inhibitor for Type 2 Diabetes
03/21/07
ActivX Biosciences Launches Breakthrough Kinase Platform, KiNativ™
